<VariationArchive RecordType="classified" VariationID="3709" VariationName="NC_000019.10:g.(11077742_11077775)_(11093595_11093630)del" VariationType="Deletion" Accession="VCV000003709" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2019-06-23" MostRecentSubmission="2019-06-23">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="18748" VariationID="3709">
      <GeneList>
        <Gene Symbol="LDLR" FullName="low density lipoprotein receptor" GeneID="3949" HGNC_ID="HGNC:6547" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>19p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="11089463" stop="11133820" display_start="11089463" display_stop="11133820" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="11200037" stop="11244505" display_start="11200037" display_stop="11244505" Strand="+" />
          </Location>
          <OMIM>606945</OMIM>
          <Haploinsufficiency last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
        <Gene Symbol="LDLR-AS1" FullName="LDLR antisense RNA 1" GeneID="115271120" HGNC_ID="HGNC:54407" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>19p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="11089068" stop="11089659" display_start="11089068" display_stop="11089659" Strand="-" />
          </Location>
        </Gene>
        <Gene Symbol="LOC126862855" FullName="BRD4-independent group 4 enhancer GRCh37_chr19:11202176-11203375" GeneID="126862855" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>19p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="11091500" stop="11093074" display_start="11091500" display_stop="11093074" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NC_000019.10:g.(11077742_11077775)_(11093595_11093630)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" outerStart="11077742" innerStart="11077775" innerStop="11093595" outerStop="11093630" display_start="11077742" display_stop="11093630" variantLength="15821" Strand="+" />
      </Location>
      <OtherNameList>
        <Name>FH Denver</Name>
        <Name>FH French Canadian 1</Name>
        <Name>PROMOTER/EX1 DEL</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.(11077742_11077775)_(11093595_11093630)del" Assembly="GRCh38">
            <Expression>NC_000019.10:g.(11077742_11077775)_(11093595_11093630)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="nssv7487198" DB="dbVar" />
        <XRef ID="nsv1197501" DB="dbVar" />
        <XRef Type="Allelic variant" ID="606945.0025" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff reviewed the sequence information reported in PubMed 14756670 to determine the location of this deletion on the current reference sequence. In Fig. 2A, the deletion can be seen to be AC011485.6:g.(86313_86280)_(102168_102135)del. This maps to NC_000019.10:g.(11077742_11077775)_(11093595_11093630)del.</Comment>
      <Comment DataSource="NCBI curation" Type="public">15.8 kb deletion in LDLR, spanning exon 1 plus flanking sequences and including the promoter region. </Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000019.10:g.(11077742_11077775)_(11093595_11093630)del AND Hypercholesterolemia, familial, 1" Accession="RCV000003899" Version="7">
        <ClassifiedConditionList TraitSetID="7435">
          <ClassifiedCondition DB="MedGen" ID="C0745103">Hypercholesterolemia, familial, 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2004-03-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2004-03-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-06-23" MostRecentSubmission="2019-06-23">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">1348044</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">14756670</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">1727071</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">2318961</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3343347</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3627182</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="7435" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15983" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIA, FAMILIAL, MODIFIER OF</ElementValue>
                <XRef Type="Allelic variant" ID="600946.0028" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">LDL RECEPTOR DISORDER</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type IIa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPER-LOW-DENSITY-LIPOPROTEINEMIA</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIC XANTHOMATOSIS, FAMILIAL</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
                <XRef Type="MIM" ID="144400" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fredrickson type IIa hyperlipoproteinemia</ElementValue>
                <XRef ID="397915002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyper-beta-lipoproteinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hypercholesterolemia, familial, 1</ElementValue>
                <XRef ID="MONDO:0007750" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FH</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FHC</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction; stroke occurs more rarely. Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids. Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH. Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (&gt;500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease.</Attribute>
                <XRef ID="NBK174884" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2019">
                <URL>https://www.nice.org.uk/guidance/CG71</URL>
                <CitationText>National Institute for Health and Clinical Excellence, Identification and management of familial hypercholesterolaemia, 2008 [Updated: 4 October 2019]</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2012">
                <ID Source="PubMed">22364837</ID>
              </Citation>
              <Citation Type="general" Abbrev="IPMFH, 2004">
                <ID Source="PubMed">15177124</ID>
              </Citation>
              <Citation Type="general" Abbrev="NLAEP, 2011">
                <ID Source="PubMed">21600525</ID>
              </Citation>
              <Citation Type="general" Abbrev="Int'l FH Foundation, 2014">
                <ID Source="PubMed">24418289</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24404629</ID>
                <ID Source="BookShelf">NBK174884</ID>
              </Citation>
              <Citation Type="general" Abbrev="Feldman et al., 2015">
                <ID Source="PubMed">25404096</ID>
              </Citation>
              <Citation Type="general" Abbrev="EAS, 2014">
                <ID Source="PubMed">25053660</ID>
              </Citation>
              <Citation Type="general" Abbrev="PLEF, 2014">
                <ID Source="PubMed">24636176</ID>
              </Citation>
              <Citation Type="general" Abbrev="PLEF, 2013">
                <ID Source="PubMed">23725921</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="CSANZ, 2016">
                <URL>https://www.csanz.edu.au/wp-content/uploads/2017/07/Familial-Hypercholesterolaemia_ratified_-25-Nov-2016.pdf</URL>
                <CitationText>The Cardiac Society of Australia and New Zealand, Diagnosis and Management of Familial Hypercholesterolaemia – Position Statement</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Familial-Hypercholesterolemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, APOB, LDLR, PCSK9 Pathogenic Variants (Familial Hypercholesterolemia), 2019</CitationText>
              </Citation>
              <XRef ID="391665" DB="Orphanet" />
              <XRef ID="C0745103" DB="MedGen" />
              <XRef ID="MONDO:0007750" DB="MONDO" />
              <XRef Type="MIM" ID="143890" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="24064" SubmissionDate="2019-06-19" DateLastUpdated="2019-06-23" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="606945.0025_FH FRENCH CANADIAN 1" title="LDLR, PROMOTER/EX1 DEL_FH FRENCH CANADIAN 1" />
        <ClinVarAccession Accession="SCV000024064" DateUpdated="2019-06-23" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000024065" DateChanged="2014-08-31" Version="2" />
        </ReplacedList>
        <Classification DateLastEvaluated="2004-03-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Deletion of the promoter and exon 1 of the LDLR gene resulting in a null allele is the mutation found in about 60% of French Canadian cases of FH (FHCL1; 143890) in Quebec (Hobbs et al., 1987; Leitersdorf et al., 1990). Leitersdorf et al. (1990) quoted work indicating that all persons with the 'French Canadian deletion' trace their ancestry to a small town northeast of Montreal called Kamouraska, thus illustrating founder effect. Founder effect was suggested as well by the fact that the mutation was also found in France where it was, however, rare (Fumeron et al., 1992). The same mutation was found in a non-French Canadian Caucasian in Denver, Colorado (Hobbs et al., 1988). Betard et al. (1992) found that the 10-kb deletion had the same haplotype, called the B haplotype. They identified 15 different haplotypes for the normal allele in heterozygotes. Thus, founder effect is again supported.</Attribute>
              <Citation>
                <ID Source="PubMed">3627182</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">2318961</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">1727071</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">3343347</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">1348044</ID>
              </Citation>
              <XRef DB="OMIM" ID="143890" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">(It is more accurate to state that Kamouraska is northeast of Quebec City on the south side of the St. Lawrence River. See 609313 for a unique form of erythrokeratodermia variabilis, designated the Kamouraska type and symbolized EKV3, that has been identified in families living in the same region of Quebec.)</Attribute>
              <XRef DB="OMIM" ID="609313" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Simard et al. (2004) identified the breakpoint of the more than 15-kb deletion involving the promoter and exon 1 of the LDLR gene, as well as the breakpoint of the 5-kb deletion of exons 2 and 3 (606945.0026), which accounts for 5% of French Canadian FH cases. Both deletions appeared to be the result of homologous recombination by unequal crossing over between the left arms of Alu repeats. Simard et al. (2004) determined that 55% of the LDLR gene is composed of Alu elements; thus, it is not surprising that most LDLR rearrangements involve at least 1 Alu. They developed a rapid PCR-based assay for these 2 'French Canadian' deletions. Screening of a representative population sample of 943 French Canadian youths whose LDL cholesterol levels were above the 50th percentile allowed Simard et al. (2004) to estimate the prevalence of the more than 15-kb allele as 0.11% (95% confidence interval, 0.03 to 0.38).</Attribute>
              <Citation>
                <ID Source="PubMed">14756670</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LDLR" />
          </GeneList>
          <Name>LDLR, PROMOTER/EX1 DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">PROMOTER/EX1 DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="606945.0025" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">FH FRENCH CANADIAN 1</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="24064" TraitType="Disease" MappingType="Name" MappingValue="FH FRENCH CANADIAN 1" MappingRef="Preferred">
        <MedGen CUI="C0745103" Name="Hypercholesterolemia, familial, 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

